Trazodone for Nighttime Anxiety Management

Introduction to Trazodone Limitations

The American Academy of Sleep Medicine recommends against using trazodone for chronic insomnia due to insufficient evidence of benefit outweighing harms 1, 4
Trazodone lacks evidence for PRN anxiety management, and its therapeutic effects for anxiety-related conditions require regular administration at doses of 150-300 mg daily 1, 2

The American Academy of Sleep Medicine recommends lorazepam 1 mg at bedtime for anticipatory anxiety, which has established efficacy for anxiety phenomena and appropriate PRN use 3
For regular nighttime anxiety management, scheduled treatment with SSRIs or SNRIs is recommended as first-line for generalized anxiety disorder, with regular dosing 3
The American Academy of Sleep Medicine recommends against trazodone for chronic insomnia and suggests preferred alternatives, including zolpidem 10 mg, eszopiclone 2-3 mg, and Cognitive Behavioral Therapy for Insomnia (CBT-I) as first-line non-pharmacologic treatment 1, 4

Trazodone is associated with a risk of priapism, which requires immediate medical attention if erections last >6 hours, and orthostatic hypotension, particularly problematic with inconsistent dosing 2
The medication can cause sedation and impaired coordination, which is dangerous with unpredictable PRN use, and has a risk of serotonin syndrome, especially when combined with other serotonergic medications 2
The American Academy of Sleep Medicine recommends avoiding sub-therapeutic doses of trazodone, as doses of 25-50 mg lack evidence for anxiety and provide minimal benefit even for insomnia 1

Trazodone may be appropriate for comorbid depression with insomnia, with scheduled dosing of 150-300 mg predominantly at bedtime for patients with major depressive disorder 2
The medication has shown benefit in reducing nightmare frequency in patients with PTSD-associated nightmares, with a mean effective dose of 212 mg/day and regular administration 2
Trazodone may be considered as a third-line insomnia treatment, only after failure of CBT-I and benzodiazepine receptor agonists, with scheduled (not PRN) dosing 4